Compounds > 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Page last updated: 2024-11-03

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Obesity

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with Obesity in 1 studies

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Netherton, SJ1
Jimmo, SL1
Palmer, D1
Tilley, DG1
Dunkerley, HA1
Raymond, DR1
Russell, JC1
Absher, PM1
Sage, EH1
Vernon, RB1
Maurice, DH1

Other Studies

1 other study available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Obesity

ArticleYear
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
    Diabetes, 2002, Volume: 51, Issue:4

    Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imi

2002